Initial approach to Epidermal Growth Factor in SARS-CoV-2 infection

Introduction: Epidermal growth factor (EGF) receptor plays a critical role in lung inflammation. Data exploring the role of its canonical ligand are scarce. Exploring potential and new biomarkers expands diagnostic and therapeutic options, providing resilience in complex healthcare contexts. Object...

Full description

Saved in:
Bibliographic Details
Main Author: Héctor José Pérez Hernández
Format: Article
Language:Spanish
Published: ECIMED 2024-10-01
Series:Revista Cubana de Medicina Militar
Subjects:
Online Access:https://revmedmilitar.sld.cu/index.php/mil/article/view/60858
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841546516186005504
author Héctor José Pérez Hernández
author_facet Héctor José Pérez Hernández
author_sort Héctor José Pérez Hernández
collection DOAJ
description Introduction: Epidermal growth factor (EGF) receptor plays a critical role in lung inflammation. Data exploring the role of its canonical ligand are scarce. Exploring potential and new biomarkers expands diagnostic and therapeutic options, providing resilience in complex healthcare contexts. Objective: To describe the behavior of serum epidermal growth factor levels and evaluate its possible impact in the context of patients hospitalized with COVID-19. Methods: Controlled exploratory study with quota sampling, in patients with COVID-19 admitted at the "Saturnino Lora Hospital", and 23 apparently healthy subjects, active donors of Blood Bank "Renato Guitar Rosell". For EGF determinations, the commercial UMELISA EGF kit from the Cuban Immunoassay Center was used. Summary measures: absolute frequency, percentage, and the arithmetic mean were used. The statistical significance of observable differences between groups was explored with the chi-square test or Welch's t test with α= 0.05. Results: 46 subjects enrolled in the study, (23) 50% positive for SARS-CoV-2 by RT-PCR. Between COVID-19 vs. control, general differences were observed regarding epidermal growth factor (g=1.4465; p= 0.0000*), similar behavior was observed with respect to sex and age. In COVID-19 regarding severity, slight differences were generally observed depending on severity (g= 0.2152), a trend that was accentuated in the case of males (g= 1.1677) and females (g= 0.7533), the latter comparatively minor. Conclusions: Determining serum EGF in patients infected by SARS-CoV-2 could have a predictive value for severity in patients with COVID-19.
format Article
id doaj-art-77606af40f7844509dc1450ea1be35d0
institution Kabale University
issn 1561-3046
language Spanish
publishDate 2024-10-01
publisher ECIMED
record_format Article
series Revista Cubana de Medicina Militar
spelling doaj-art-77606af40f7844509dc1450ea1be35d02025-01-10T19:00:45ZspaECIMEDRevista Cubana de Medicina Militar1561-30462024-10-015341050Initial approach to Epidermal Growth Factor in SARS-CoV-2 infectionHéctor José Pérez Hernándezhttps://orcid.org/0000-0002-4628-7436Introduction: Epidermal growth factor (EGF) receptor plays a critical role in lung inflammation. Data exploring the role of its canonical ligand are scarce. Exploring potential and new biomarkers expands diagnostic and therapeutic options, providing resilience in complex healthcare contexts. Objective: To describe the behavior of serum epidermal growth factor levels and evaluate its possible impact in the context of patients hospitalized with COVID-19. Methods: Controlled exploratory study with quota sampling, in patients with COVID-19 admitted at the "Saturnino Lora Hospital", and 23 apparently healthy subjects, active donors of Blood Bank "Renato Guitar Rosell". For EGF determinations, the commercial UMELISA EGF kit from the Cuban Immunoassay Center was used. Summary measures: absolute frequency, percentage, and the arithmetic mean were used. The statistical significance of observable differences between groups was explored with the chi-square test or Welch's t test with α= 0.05. Results: 46 subjects enrolled in the study, (23) 50% positive for SARS-CoV-2 by RT-PCR. Between COVID-19 vs. control, general differences were observed regarding epidermal growth factor (g=1.4465; p= 0.0000*), similar behavior was observed with respect to sex and age. In COVID-19 regarding severity, slight differences were generally observed depending on severity (g= 0.2152), a trend that was accentuated in the case of males (g= 1.1677) and females (g= 0.7533), the latter comparatively minor. Conclusions: Determining serum EGF in patients infected by SARS-CoV-2 could have a predictive value for severity in patients with COVID-19.https://revmedmilitar.sld.cu/index.php/mil/article/view/60858COVID-19epidermal growth factorinflammationserum biomarkers.
spellingShingle Héctor José Pérez Hernández
Initial approach to Epidermal Growth Factor in SARS-CoV-2 infection
Revista Cubana de Medicina Militar
COVID-19
epidermal growth factor
inflammation
serum biomarkers.
title Initial approach to Epidermal Growth Factor in SARS-CoV-2 infection
title_full Initial approach to Epidermal Growth Factor in SARS-CoV-2 infection
title_fullStr Initial approach to Epidermal Growth Factor in SARS-CoV-2 infection
title_full_unstemmed Initial approach to Epidermal Growth Factor in SARS-CoV-2 infection
title_short Initial approach to Epidermal Growth Factor in SARS-CoV-2 infection
title_sort initial approach to epidermal growth factor in sars cov 2 infection
topic COVID-19
epidermal growth factor
inflammation
serum biomarkers.
url https://revmedmilitar.sld.cu/index.php/mil/article/view/60858
work_keys_str_mv AT hactorjosaparezhernandez initialapproachtoepidermalgrowthfactorinsarscov2infection